Edgen Stock·Dec 12 2025, 12:46Back
PTC Therapeutics Secures Canadian Approval For PKU Drug
Edgen Stock·Dec 12 2025, 12:46
[1] Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS - BioSpace (https://www.biospace.com/press-releases/canad ...)[2] TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer - BioSpace (https://www.biospace.com/press-releases/tukys ...)[3] Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test - Fierce Biotech (https://www.fiercebiotech.com/biotech/rezolut ...)
